161 Cheshire Lane  
Suite 100  
Plymouth, MN 55441  
USA  
www.medtronic.com  
Official Title:  A Post -market Feasibility Study Evaluating Location Accuracy Using the superDimension™ 
Navigation System Version 7.2 With  Fluoroscopic Navigation Technology in Subjects Undergoing Lung Lesion 
Biopsy  
 
ClinicalTrials.gov ID: [STUDY_ID_REMOVED] 
 
Date of Document: 09Apr2018  
  
Fluoroscopic Navigation Clinical Investigation Plan 
MDT18004ILSFNV Version  1.0 Page 1 of 54 
This document is electronically controlled  056-F275, v3.0 Clinical Investigation Plan TemplateClinical I
nvestigation Plan  
Clinical Investigation Plan/Study Title A post-market  fe asibility study  evaluating 
location accuracy using  the superDimension™ 
Navigation System Version 7.2 with Fluoroscopic 
Navigation  Technology in subjects undergoing 
lung lesion biopsy  
Clinical Investigation Plan Identifier  MDT18004ILSFNV  
Study Product Name  superDimension™ Navigation System Version 7.2  
with Fluoroscopic Navigation Technology  
Sponsor/Local Sponsor  Medtronic  
Lung Health  
Minimally Invasive Therapies Gro up 
161 Cheshire Lane , Suite 100 
Plymouth, MN 55441 
Document Version  Final Version 1.0 , 09-APR -2018 
Co-Principal Investigator s Michael A. Pritchett DO  MPH  
Pulmonary Disease & Critical Care Medicine  
FirstHealth Moore Regional Hospital  
Pinehurst Medical C linic 
Krishnendu Bhadra MD  
Interventional Pulmonology  
CHI Memorial Medical Group  
 
 
 
 
Covidien llc is an indirect wholly owned subsidiary of Medtronic plc.  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 2 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  1. Investigator Statement  
Study product Name  superDimension™ Navigation System Version 7.2  with 
Fluoroscopic Navigation Technology  
Sponsor  Medtronic  
Lung Health  
Minimally Invasive Therapies Group   
161 Cheshire Lane, Suite 100 
Plymouth, MN 55441 
Clinical Investigation Plan Identifier   MDT18004ILSFNV  
Version Number/Date  Final Version 1.0, 09 -APR -2018 
I have read the protocol, including all appendices, and I agree that it contains all necessary details for me and my staff to conduct this study as described. I will conduct this study as outlined herein and will make a reasonable effort to complete the study within the time designated.  
I agree to comply with ISO 14155:2011 (Clinical Investigation of Medical Devices for Human Subjects – 
Good Clinical Practice) and the International Conference on Harmonisation (ICH) of Technical 
Requirements For Registration of Pharmaceuticals For Human Use, ICH Harmonised Tripartite 
Guideline for Good Clinical Practice E6 (R1). I agree to ensure that the con fidential information 
contained in this document will not be used for any purpose other than the evaluation and conduct of the clinical investigation without the prior written consent of Medtronic.  
I will provide all study personnel under my supervision co pies of the protocol and access to all 
information provided by Medtronic. I will discuss this material with them to ensure that they are fully informed about the products and the study.  
Principal Investigator’s Signature:   
Principal Investigator’s Name:   
Institution:   
Date:    
  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 3 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Table of Contents  
1. Investigator Statement  ......................................................................................................  2 
2. Glossary ..............................................................................................................................  6 
2.1. Terms  .................................................................................................................................. 6  
2.2. Definitions  ............................................................................................................................ 7  
3. Synopsis  ...........................................................................................................................  10 
4. Introduction  .....................................................................................................................  15 
4.1. Background  ........................................................................................................................  15 
4.2. Purpose  .............................................................................................................................. 16 
5. Objectives and Endpoints  ................................................................................................ . 16 
5.1. Primary Objective  ................................................................................................................  16 
5.2. Primary Endpoint  ................................................................................................................  16 
5.3. Secondary Endpoints  ...........................................................................................................  18 
5.4. Safety Endpoints  ................................................................................................................. 18 
6. Study Design  .................................................................................................................... 19 
6.1. Duration  .............................................................................................................................  19 
6.2. Rationale  ............................................................................................................................ 19 
7. Product Description ..........................................................................................................  20 
7.1. General  .............................................................................................................................. 20 
7.2. Dosage Form and Route of Administration .............................................................................  22 
7.3. Manufacturer  ...................................................................................................................... 22 
7.4. Packaging  ........................................................................................................................... 22 
7.5. Intended Population  ............................................................................................................ 22 
7.6. Equipment  ..........................................................................................................................  22 
7.7. Product Use  ........................................................................................................................  23 
7.8. Product Training Requirements  .............................................................................................  25 
7.9. Product Receipt and Tracking  ...............................................................................................  26 
7.10.  Product Stora ge .............................................................................................................  26 
7.11.  Product Return ..............................................................................................................  26 
7.12.  Product Accountability  .................................................................................................... 26 
7.13.  Intended Claims ............................................................................................................ 26 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 4 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  8. Selection of Subjects  ........................................................................................................  26 
8.1. Study Population ................................................................................................................. 26 
8.2. Subject Enrollment  ..............................................................................................................  27 
8.2.1.  Roll-in Subjects  ...................................................................................................................... 27 
8.3. Inclusion Criteria  ................................................................................................................. 27 
8.4. Exclusion Criteria ................................................................................................................. 27 
9. Study Procedures  .............................................................................................................  28 
9.1. Schedule of Events  ..............................................................................................................  28 
9.1.1.  Overview of Study Procedures  .............................................................................................. 29 
9.2. Subject Scr eening  ...............................................................................................................  30 
9.3. Prior and Concomitant Medications  .......................................................................................  30 
9.4. Subject Consent  ..................................................................................................................  30 
9.5. Randomization and Treatment Assignment  ............................................................................ 30 
9.6. Medication Compliance  ........................................................................................................  31 
9.7. Assessment of Efficacy  ........................................................................................................  31 
9.7.1.  Baseline ................................................................................................................................. 31 
9.7.2.  Procedure Day  ....................................................................................................................... 31 
9.7.3.  Procedure Details  .................................................................................................................. 31 
9.7.4.  Study Completion  .................................................................................................................. 32 
9.8. Assessment of Safety  ..........................................................................................................  32 
9.9. Recording Data  ...................................................................................................................  32 
9.10.  Deviation Handling  ........................................................................................................  33 
9.11.  Subject Withdrawal or Discontinuation  .............................................................................  33 
10. Risks and Benefits  ............................................................................................................ 34 
10.1.  Potential Risks  ...............................................................................................................  34 
10.1.1.  Summary MDR Reportable Event Trend & Risk Analysis Report ....................................... 34 
10.1.2.  Study -related Imaging  ....................................................................................................... 37 
10.2.  Potential Benefits  ...........................................................................................................  38 
10.3.  Risk-Benefit Rationale  .................................................................................................... 38 
11. Adverse Events and Device Deficiencies  .......................................................................... 38 
11.1.  Definitions/Classifications  ...............................................................................................  38 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 5 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  11.1.1.  Adverse Event (AE)  ............................................................................................................ 39 
11.1.2.  Serious Adverse Event (SAE)  .............................................................................................. 39 
11.1.3.  Adverse Device Effect (ADE)  .............................................................................................. 39 
11.1.4.  Serious Adverse Device Effect (SADE)  ............................................................................... 40 
11.1.5.  Unanticipated Serious Adverse Device Effect (USADE)  ..................................................... 40 
11.1.6.  Device Deficiency  ............................................................................................................... 40 
11.1.7.  Adverse Event Relationship Classification  ......................................................................... 40 
11.1.8.  Adverse Event Outcome Classification  .............................................................................. 42 
11.2.  Reporting of Adverse Events  ........................................................................................... 42 
11.2.1.  Notification to Authorities  ................................................................................................. 43 
12. Data Review Committees  ................................................................................................ . 44 
13. Statistical Design and Methods  ........................................................................................  44 
14. Ethics  ................................................................................................................................  45 
14.1.  Statement(s) of Compliance  ........................................................................................... 45 
15. Study Administration  ....................................................................................................... 46 
15.1.  Monitoring  .................................................................................................................... 46 
15.2.  Data Management  ......................................................................................................... 47 
15.3.  Direct Access to Source Data/Documents  ......................................................................... 47 
15.4.  Confidentiality ...............................................................................................................  47 
15.5.  Liability ......................................................................................................................... 48 
15.6.  CIP Amendments  ...........................................................................................................  48 
15.7.  Record Retention  ...........................................................................................................  48 
15.8.  Publication and Use of Information  ..................................................................................  48 
15.9.  Suspension or Early Termination  .....................................................................................  49 
15.10.  Study Contact Information  .............................................................................................. 50 
16. References  ....................................................................................................................... 50 
17. Appendices  ....................................................................................................................... 53 
17.1.  Sample Patient Informed Consent  ...................................................................................  53 
17.2.  User Man ual ..................................................................................................................  53 
18. Version History  .................................................................................................................  54 
 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 6 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  2. Glossary 
2.1. Terms  
Acronym / Term  Definition  
AE adverse  event  
AP anteroposterior  
CBCT  cone -beam computed tomography  
CIP clinical  investigation plan  
CT computed  tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
EC Ethics  Committee  
ENB electromagnetic navigation bronchoscopy  
eCRF  electronic case report form  
EWC  extended working channel  
FDA Food and Drug Administration 
GCP good  clinical  practice  
ICF informed  consent  form  
ICH International  Conference  on Harmonisation 
IFU instructions  for use 
ILS Medtronic Interventional Lung Solut ions 
IRB institutional  review board  
LG locatable guide  
MDR  medical device reporting  
ROSE  rapid on -site evaluation  
SAE serious  adverse event  
SAP statistical  analysis plan  
 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 7 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  2.2. Definitions  
Adequate Periprocedural Location  
The location of the extended working channel when  the proceduralist makes the decision that 
placement is adequate and clinically acceptable to proceed with tissue sampling based on location 
confirmation by cone -beam computed tomography ( CBCT ). 
Adverse Event  
Please refer to Section 11.1.1. 
Bronchopulmonary Hemorrhage  
A disorder characterized by bleeding from the bronchial wall and/or lung parenchyma. Degree of severity will be classified according to Common Terminology Criteria for Adverse Event s (CTCAE) grade 
as follows (a semicolon indicates “or” within the description of the grade):  
• Grade 1: Mild symptoms; intervention not indicated  
• Grade 2: Moderate symptoms; medical intervention indicated  
• Grade 3: Transfusion, invasive  intervention indicated  (e.g., hemostasis of bleeding site)  
• Grade 4: Life -threatening respiratory or hemodynamic compromise; intubation or urgent 
intervention indicated  
• Grade 5: Death  
Common Terminology Criteria for Adverse Events  
A set of criteria for the standardized classific ation of adverse effects of drugs used in cancer therapy. 
The CTCAE system is a product of the US National Cancer Institute (NCI)  Cancer Therapy Evaluation 
Program (CTEP) .1 This protocol will use Version 5.0, available at 
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50https://ctep.canc
er.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50   
ENB Procedure Time  
Total time from the first entry of the extended working channel or locatable guide u ntil the last exit of 
the extended working channel.  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 8 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Device Deficiency  
See Section 11.1.6 . 
Investigational Medical Device 
For the purpose of this clinical investigation plan, an Investigational Medical Device is defined as, “ a 
device, including a transitional device, which is the object of an investigation.” The Investigational 
Medical Device being evaluated in this study is the superDimension™ Navigation System Version 7.2 
with Fluoroscopic Navigation Technology, which has been cleared by the FDA.  
Lesion Size  
Defined as greatest diameter of target lesion. 
Navigation Success  
The proportion of cases in which the operator is able to successfully navigate to the lung target with ENB 
guidance and obtain tissue for biopsy . 
Pneumothorax  
A disorder characterized by abnormal presence of air in the pleural cavity resulting in the collapse of the 
lung. Degree of severity will be classified according to CTCAE grade as follows (a semicolon indicates “or” within the description of the grade):  
• Grade 1: Asymptomatic; clinical or diagnostic observations only; intervention not indicated  
• Grade 2: Symptomatic; intervention indicated (e.g., tube placement without sclerosis)  
• Grade 3: Sclerosis and/or operative intervention indicated; hospitalization indicated  
• Grade 4: Life -threatening consequences; urgent intervention indicated  
• Grade 5: Death  
Relational Accuracy  
Describes the 3 -dimensional relationship between the catheter and the lesion in terms of distance, 
vector, and trajectory.  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 9 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Respiratory Failure  
A disorder characterized by impaired gas exchange by the respiratory system resulting in hypoxia and a 
decrease in oxygenation of the tissues that may be associated with an increase in arterial levels of 
carbon dioxide. Degree of severity will be classified  according to CTCAE grade as follows (a semicolon 
indicates “or” within the description of the grade):  
• Grade 4: Life -threatening consequences; urgent intervention, intubation, or ventilatory support 
indicated 
• Grade 5: Death  
Serious Adverse Event  
Please refer to Section 11.1.2. 
Technical Success  
Successful completion of Local Registration utilizing Fluoroscopic Navigation Technology  in 
superDimension™ Navigation System Version 7.2 . 
Total Procedure Time  
Total time from the first entry of the bronchoscope to the last exit of the bronchoscope. 
  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 10 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  3. Synopsis  
Title A post-market feasibility study evaluating location accuracy using the 
superDimension™ Navigation System Version 7.2 with Fluoroscopic 
Navigation Technology in subjects undergoing lung lesion biopsy  
Clinical Study Type  Post -Market Feasibility 
Product Name  superDimension™ Navigation System Version 7.2  with Fluoroscopic 
Navigation  Technology  
Sponsor  Medtronic  
Lung Health  
Minimally Invasive Therapies Group   
161 Cheshire Lane, Suite 100 
Plymouth, MN 55441 
Investigation Purpose  The purpose of this investigation is to confirm the clinical accuracy of 
the superDimension™ Navigation System Version 7.2 with 
Fluoroscopic Navigation Technology.  
Product Status  superDimension™ Navigati on System Version 7.2 is cleared by FDA  
Primary Objective The primary objective of this post -market feasibility study is to 
confirm the location accuracy of the local registration feature of the 
superDimension™ Navigation System Version 7.2 in subjects 
undergoing lung lesion biopsy. 
Primary Endpoint  The Primary Endpoint is the measured ability of the superDimension ™ 
Navigation System v 7.2 with Fluoroscopic Navigation  Technology to 
place the center of the virtual navigation target  (green ball ) on the 
inten ded target lesion as confirmed by cone-beam computed 
tomography  (CBCT) .  
The primary endpoint will be evaluated in Technicall y Successful cases  
(local registration complete).  
Secondary Objective s The following secondary endpoints will be evaluated in all enrolled 
subjects : 
• Number of cases that are technically successful (successful 
completion of local registration)  
• In cases that are not technically successful, r eason for 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 11 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  incomplete local registration  in each target lesion  
• Investigator confirmation that the catheter is in an “Adequate 
Periprocedural  Location”  (the location of the extended 
working channel with the proceduralist makes the  decision 
that placement is adequate and clinically acceptable to 
proceed with tissue sampling based on location confirmatio n 
by CBCT ) 
• Total procedure tim e 
• ENB procedure time  
• Total fluoroscopy time , as measured by the fluoroscopy 
system  
• Adequacy  of the ENB -aided tissue sample  for rapid on-site 
evaluation (ROSE) of cytologic samples by pathology  (when 
applicable)  
• Histopathologic al call based on ROSE of the ENB -aided tissue 
sample (when applicable)  
• Final pathology results of the ENB -aided tissue sample  
• Biopsy tools used, tool order, number of passes, and 
diagnoses for each tool based on ROSE and final pathology of 
the ENB-aided sample  
In Technically Successful  cases  (local registration complete) : 
• Percentage of cases in which the intended lesion is correctly 
identified (as opposed to a non -target lesion or normal lung 
tissue) as indicated by the system software. 
• Relational Accuracy in cases  in which the Intended lesion is 
targeted.  
 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 12 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Safety Assessments  The following safety endpoints will be evaluated in all enrolled 
subjects. These events will be evaluated for their relationship to the 
study device and study procedure, and classified  according to 
Common Terminology Criteria for Adverse Events (CTCAE) Version 5.  
• Incidence of all pneumothorax related to ENB index 
procedure  
• Incidence of CTCAE Grade ≥2 pneumothorax related to the ENB index procedure  
• Incidence of all bronchopulmonary hemorrhage related to ENB index procedure  
• Incidence of CTCAE Grade ≥2 bronchopulmonary hemorrhage related to the ENB index procedure  
• Incidence o f CTCAE Grade≥4 respiratory failure related to ENB 
index procedure  
In addition to the Safety Endpoints described above, all Adverse Events related to the superDimension™ navigation system, associated tools, or ENB procedure will be collected.  
Adverse events and safety endpoints will be collected immediately post -procedure  and at 7 days  post procedure. 
Study Design  This post- market feasibility study will include subjects who meet the 
criteria specified below. Assessments will occur at baseline, during and immediately after the procedure, and at 7 days post procedure by 
telephone. 
Randomization  Not Applicable  
Clinical Sites  Up to 5 clinical sites in the United States are planned  
Sample Size  This study will enroll up to 50 subjects meeting the inclusion c riteria, 
with a maximum of 25 subjects per site. 
A maximum of five roll -in cases will be allowed per investigator, as 
described in  Section 8.2.1 . 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 13 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Inclusion/Exclusion Criteria  Inclusion Criteria  
1. Subject presents with lung lesio n(s) greater than 10  mm in 
diameter amenable to evaluation by ENB at the time of 
evaluation 
2. Lesion is intended to be biopsied by the participating investigator 
3. Subject is willing and able to provide informed consent to 
participate in the study  
4. Subject is a  candidate for an elective ENB procedure 
5. Subject is over the age of 18  
Exclusion Criteria  
1. Central lesions that are not visible endobronchially  or could  
be reached by a flexible bronchoscope or endobronchial 
ultrasound (EBUS) without the utilization of ENB  
2. Lesions within 10  mm of the diaphragm 
3. The subject is unable or unwilling to comply with study 
follow-up schedule  
4. The subject has participated in an investigational drug or 
device research study within 30 days of enrollment that 
would interfere with this st udy 
5. Female subjects who are pregnant or nursing as determined 
by standard site practices   
Study Procedures and 
Assessments Enrolled subjects will first undergo a standard ENB procedure to navigate to within 2.5 cm of the target lesion. Local registration with Fluoroscopic Navigation Technology will be conducted and fluoroscopy and CBCT scans will be used  to document that the biopsy 
tool is correctly positioned in the target lesion in three dimensions. Efficacy endpoints will be collected during the procedure and safety will be evaluated through 7 -day follow -up, as described above.  
Statistics  No formal statistical comparisons or sample size calculations will be made for this post-market feasibility study.  
Interim Analysis:  Will be conducted after roll-in procedures  have 
been completed for the purpos e of evaluating workflow  and data 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 14 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  validity . 
Final Analysis: W ill be conducted after all subjects have completed 
the procedur e and the 7 -day follow -up for the purpose of evaluating 
the primary and secondary endpoi nts. 
  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 15 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
   
4. Introduction  
4.1. Background  
Electromagnetic navigation bronchoscopy (ENB) using the superDimension™ navigation system is an 
image-guided approach that uses three- dimensional reconstructed computed tomography (CT) scans 
and sensor location technology  to guide endoscopic tools to lung lesions .2 To date, over thirty clinical 
studies  with data from over 2,100 subjects  have been published describing outcomes of ENB -aided 
biopsy of peripheral lung lesions  using the superDimension ™ navigation system . ENB -aided diagnostic 
yield ranges from 39% to 97%.3-34 Pneumothorax is the most common complication, occurring in 
approximately 3% of patients in a recent meta -analysis,35 lower th an the pooled 20% rate reported for 
transthoracic needle biopsy .36 The prospective, multicenter NAVIGATE study evaluated ENB using the 
superDimension ™ navigation system  v7.0 and v6.0. Pneumothorax CTCAE Grade ≥2 occurred in 3.2% of 
subjects. Any -grade pneumothorax occurred in 4.9% of subjects. Bronchopulmonary hemorrhage was 
1.0% CTCAE Grade ≥2 and 2.3% overall. CTCAE Grade ≥4 respiratory failure occurred in 0.6% of subjects. 
There were n o deaths  related to the  ENB device or associated tools .37  
Despite the volume of safety and efficacy data on the superDimension™ navigation system, one remaining challenge is that the reconstructed images are based on pre-procedure CT scans of the 
patient without real -time confirmation of catheter location relative to the target lesion. I n addition, CT -
to-body divergence can occur when the patient’s anatomy does not perfectly align with the three-
dimensional CT. Because the inhale level during the CT scan is different than during the procedure, the volume and shape of the lung are different. Other factors resulting in deformation or divergence from 
the original CT may include the presence and push by the bronchoscope or catheter, the reaction of 
airway muscles  to sedation or anesthesia, a different patient position, bed curvature, and anato mical 
changes . 
While real- time fluoroscopy is frequently used during ENB to circumvent these challenges, small lesions 
or those obscured by dense tissue, blood vessels, or bone may not be clearly visible under two-
dimensional fluoroscopy.
38 Anatomy can also be blurred together rather than clearly separated. In the 
NAVIGATE study, at least 40% of lung lesions were not visible on fluoroscopy.37 
The superDimension™ navigation system version 7.2 is a modification of the version 7.1 system. Version 
7.2 (v7.2) adds fluoroscopic navigation technology  with enhanced three- dimensional fluoroscopy to 
improve the physician’s ability to biopsy lung lesions by rotating the fluoroscope laterally around the 
lesions. The fluoroscopic navigation technology allows for optional local registration that updates the 
catheter position relative to the target using fluoroscopic images with ENB to compensate for CT-to -
body divergence during the procedure. The local registration process focuses on a smal l region of 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 16 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  interest around the target and refines the three-dimensional model based on the fluoroscopic image 
data. This takes into consideration any changes in the patient ’s positioning or other changes compared 
to the CT scan. Because the data is taken at the time of the procedure and covers a specific region of the lung, the system can create a more precise model around the target thus minimizing local CT-to -body 
divergence.  
The current feasibility study will evaluate the location accuracy of the super Dimension™ Navigation 
System v7.2  with Fluoroscopic Navigation Technology  to determine if the local registration feature 
allows accurate lesion targeting, with the same safety profile observed for previous superDimension 
navigation system versions.   
4.2. Purpos e 
The purpose of this investigation is to confirm the clinical accuracy of the superDimension™ Navigation System v7.2 with Fluoroscopic Navigation Technology . 
5. Objectives and Endpoints  
5.1. Primary Objective  
The primary objective of this post -market feasibility study is to confirm the location accuracy of the local 
registration feature of the superDimension™ navigation system v7.2 in subjects undergoing lung lesion 
biopsy . 
5.2. Primary Endpoint  
The Primary Endpoint is the measured ability of the superDimension ™ Naviga tion System v 7.2 with 
Fluoroscopic Navigation Technology to place the center of the virtual navigation target  (green ball ) on 
the intended target lesion as confirmed by CBCT.  
The primary endpoint will be evaluated in Technically Successful cases (local re gistration complete). 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 17 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
   
 
 
 
 
 
 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 18 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  5.3. Secondary Endpoints  
The following secondary endpoints will be evaluated in all enrolled subjects:  
• Number of cases that are technically successful (successful completion of local registration)  
• In cases that are not technically successful, reason for incomplete local registration in each 
target lesion  
• Investigator confirmation that the catheter is in an “Adequate Periprocedural Location”  (the 
location of the extended working channel with the proceduralist makes the decision that placement is adequate and clinically acceptable to proceed with tissue sampling based on location confirmation by CBCT). 
• Total procedure time  
• ENB procedure time  
• Total fluoroscopy time, as measured by the fluoroscopy system  
• Adequacy of the ENB -aided tissue sample for rapid on -site evaluation (ROSE) of cytologic 
samples by pathology  (when applicable)  
• Histopathological call ba sed on ROSE of the ENB -aided tissue sample  (when applicable)  
• Final pathology results of the ENB -aided tissue sample  
• Biopsy tools used, tool order, number of passes, and diagnoses for each tool based on ROSE and final pathology of the ENB-aided sample 
In Technically Successful cases (local registration complete):  
• Percentage of cases in which the intended lesion is correctly identified (as opposed to a non -
target lesion or normal lung tissue) as indicated by the system software. 
• Relational Accuracy in cases  in which the Intended lesion is targeted.  
5.4. Safety Endpoints  
The following safety endpoints will be evaluated in all enrolled subjects. These events will be evaluated 
for their relationship to the study device and study procedure, and classified according to Common 
Terminology Criteria for Adverse Events (CTCAE) Version 5. Adverse events and safety endpoints will be 
collected immediately post-procedure and at 7 days post procedure. 
• Incidence of all pneumothorax related to ENB index procedure  
• Incidence of CTCAE  Grade ≥2 pneumothorax related to the ENB index procedure  
• Incidence of all bronchopulmonary hemorrhage related to ENB index procedure 
• Incidence of CTCAE Grade ≥2 bronchopulmonary hemorrhage related to the ENB index 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 19 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  procedure  
• Incidence of CTCAE Grade ≥4 respirat ory failure related to ENB index procedure   
In addition to the Safety Endpoints described above, all Adverse Events related to the superDimension™ 
navigation system, associated tools, or ENB procedure will be collected as described in Section 11. 
6. Study Design  
This post- market  feasibility study is planned in up to 50 subjects  meeting the inclusion criteria and 
undergoing elective ENB with the  superDimension ™ Navigation System v 7.2 with Fluoro scopic 
Navigation Technology . The stu dy will confirm the  location accuracy of the optional local registration 
feature. Enrolled subjects will first undergo a standard ENB procedure to navigate to  within 2.5 cm of 
the target lesion. Local registration with Fluoroscopic Navigation Technology  will be conducted  and 
fluoroscopy and CBCT scans will be used to document that the biopsy tool is correctly positioned in the 
target lesion in three dimensions. Details of the procedure are included in Section 9.7.3 . Periprocedur al 
endpoints will include confirmation of  accurate positioning within the target lesion,  technical success , 
relational a ccuracy , adequate periprocedural location, procedure time, adequacy of tissue capture for 
pathology, tool usage, and histopathological r esults , as described below . Safety will be evaluated 
immediately post -procedure  and at 7 days post -procedure.  
6.1. Duration  
Assessments will occur at baseline, during the procedure,  immediately post-procedure, and 7 days post 
procedure by telephone. 
Based on the expected enrollment rate of 5 subjects per site per month, the total duration of the study 
from first subject enrollment to last subject follow -up is expected to be approximately 6-8 months . 
6.2. Rationale  
The purpose of this investigation is to confirm the clinical accuracy of the superDimension™ Navigation 
System v 7.2 with Fluoroscopic Navigation Technology .  
Several aspects of the study design make it desirable compared to other options. The v 7.2 software 
includes an optional local registration feature intended to compensate for CT-to -body divergence 
though incorporation of additional fluoroscopic imaging data taken during the electromagnetic 
navigation procedure. The primary objective of this post -market feasibility study is to confirm the 
location accura cy of the local registration feature of the superDimension™ navigation system v 7.2 in 
subjects undergoing lung lesion biopsy . This objective focuses on the intended use of the system  at an 
immediate periprocedure timepoint, reducing the burden on subjects.  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 20 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Enrollment of eligible subjects with minimal inclusion and exclusion criteria will ensure a more 
representative and generalizable sample. The targeted number of 50 subjects ( 25 per site) was chosen 
as the minimal number required to evaluate the technology  at each site and is consistent with first 
experience studies evaluating the ENB technology .3-5, 7 
Design verification and validation test results provide reasonable assurance that the device conforms to 
the requirements for its indications for use and intended use. A thorough risk assessment has shown 
that the addition of the local registration feature does not significantly change the device risks . Design 
verification performed on the superDimension™ navigation system v7.2 confirmed that the 
superDimension ™ navigation system met its product specification and system requirements. Regression 
testing was executed to v erify the modifications did not impact unmodified software elements. Design 
validation was successfully performed under simulated use conditions by representative users from 
targeted user groups including qualified bronchoscopists and clinicians. Each user  group performed 
typical use scenarios defined in the design validation protocol. In conclusion, the design validation study ensured that the superDimension™ navigation system v 7.2 conformed to defined user needs and 
intended uses. 
Bench testing for the su perDimension™ navigation system v 7.2 consisted of verification of software and 
hardware elements of the product to confirm that the device performs as intended.  Formal execution of 
software test cases, including regression testing, was completed in two tes t cycles to verify that the 
software meets the designated requirements. Hardware verification testing was performed on the only 
new hardware component of the system, the fiducial marker board, to demonstrate the component 
meets all design requirements. Overall, the results of the bench testing, including all related risk activities, showed that the superDimension ™ navigation system v 7.2 meets the design requirements for 
all hardware and software components and performs as intended.  
Prior clinical studies of  the superDimension ™ navigation system are described in Section 4.1.  
The current study will evaluate the location accuracy superDimension™ Navigation System v 7.2 to 
determine if the local registration feature allows more accurate lesion targeting, with the same safety profile observed for previous superDimension™ navigation system versions.  
7. Product Description  
7.1. General  
superDimension™ navigation system v7.2 is a device that guides endoscopic tools to a target in or adjacent to t he bronchial tree on a path identified by a previous CT scan. The superDimension™ 
navigation system v7.2 allows visualization of the target and the interior of the bronchial tree; placement of catheters in the bronchial tree; and placement of radiosurgical  and dye markers into soft 
lung tissue to guide radiosurgery and thoracic surgery. 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 21 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  The v7.2 software includes an optional local registration feature intended to compensate for CT-to -body 
divergence . Incorporation of additional fluoroscopic imaging data taken during the electromagnetic 
navigation procedure  allows for 3D reconstruction of a small region of interest in the lung to 
compensate for possible CT-to -body divergence. Local registration is an optional feature and can be 
used at the physician’s discret ion.  
The superDimension™ navigation system v7.2 includes a Procedure application software modification 
and one additional stand -alone hardware component, called a fiducial marker board. The local 
registration feature uses a fluoroscopic video taken during the procedure and a fiducial marker board to 
allow 3D reconstruction of a small region of interest . 
Reconstructing three- dimensional  data from the multiple fluoroscopic 2D images requires knowing the 
position of the fluoroscope for every image relative to  a fixed coordinate system. The fluoroscope 
projection angle is measured by detecting (through image processing) a grid of non -ferromagnetic 
spheres incorporated into the fiducial marker board .  
 
This grid of spheres, which is clearly visible under fluoroscopy, is used to determine the fluoroscope 
(camera) position and angle for each fluoroscopic video frame. The grid structure is laid out as a regular 
grid (15 mm separation in 2 dimensions) and treated as infinite in the fluoroscope plane. This means that the algorithm can use any visible portion of the grid to determine the angle. The grid is attached to 
the existing location board in a way that aligns the ENB coordinate system. The location board is part of 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 22 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  the localization system that is placed underneath the patient bed mattress. Solving for the fluoroscope 
position and angle relative to the grid, provides the exact orientation for the fluoroscope in the ENB 
antenna coordinates. This enables the system to create a 3D reconstruction aligned with the ENB 
coordinate system. Therefore, the ENB catheter position relative to the target in the ENB coordinates system is known and adjusted in the ENB coordinate system accordingly.  
7.2. Dosage Form and Route of Administration 
Not Applicable. 
7.3. Manufacturer  
The superDimension™ Navigation System v7.2 with Fluoroscopic Navigation Technology  is manufactured 
by Covidien llc , an indirect wholly owned subsidiary of Medtronic plc.  
7.4. Packaging  
The device includes hardware, Planning and Procedure software, disposable sterile devices, and 
disposable non -sterile components . 
7.5. Intended Population  
The superDimension™ Navigation System v7.2 with Fluoroscopi c Navigation  Technology  is indicated for 
patients when it is necessary to guide an endoscopic tool in the pulmonary tract when the indications 
for such an examination are present in the patient. Not for pediatric use.  
7.6. Equipment  
Equipment for the study incl udes:  
• CBCT system, such as the Philips Allura Xper FD20 Fluoroscopy System   
• The superDimension™ navigation system v7.2 ( Figure 4 ): Includes a Procedure application 
software modification and one additional stand -alone hardware component, called a fiducial 
marker board. 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 23 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Software
HardwareLocal Registration  Module
Edge / LGIPC
MouseKeyboard Touch Monitor
Foot Pedal
PSTLocation Board
Key
No change PlanningProcedure – Minor change 
Data interface with the local 
registration 
 feature
Graphic cardVideo card
Fiducial Marker 
Board 
Minor change
 New
LSSsuperDimension Navigation System
 
Figure 4 . superDimension™ navigation system v7.2 components  
7.7. Product Use  
The local registration feature requires a fluoroscopic video focused on the  region of interest taken at the 
time of the ENB procedure. The fluoroscopic video is sent to the superDimension ™ console through the 
video input channel. The physician then identifies or marks the tip of the catheter and the target. To 
facilitate this mar king, the module provides visualization of soft tissue in the lung by an image 
processing mechanism. The image processing reconstructs a 3D volume and enables image slice display 
throughout that volume. As part of the visualization mechanism, each point in each image is associated 
with a point in three -dimensional  space created from the fluoroscopic video.  
Once the three -dimensional location of the catheter and target are established, the local registration 
feature performs an update of the catheter positio n in the ENB system. The update is based on the 
three -dimensional  position of the catheter relative to the target obtained from the reconstructed three-
dimensional  data.  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 24 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  The ENB procedure consists of the following primary procedure steps  (Figure 5). 
This is a brief explanation of the proposed standard-of -care use and is not the procedure  
to be used in the current clinical study.  
 
 
Figure 5 : ENB Procedure Steps  
 
A brief explanation of the ENB procedure steps is provided  below. 
1. Start Procedure Application:  The physician logs onto the system and selects the procedure 
button from the home screen.  
2. Setup:  During setup, the physician verifies that the equipment and room are correct as previously qualified. The physician also loads the specific patient plan created in the planning 
software .  
3. Registration:  During the registration, the locatable guide is placed inside the extended working catheter which is then inserted through the bronchoscope channel. The locatable guide contains a sensor in the tip that reads the magnetic field generated by the localization system. 
This allows the system to determine the locatable guide’s position. During registration, the 
locatable guide gathers survey data from  the patient which is matched with the three -
dimensional  map generated from the CT scan during planning. When the registration is 
completed successfully, the physician can begin navigation.  
4. Navigation:  During navigation, the physician uses the images of the patient’s lungs displayed in 
the system views on the computer screen to steer the locatable guide catheter to the 
predetermined target.  
5. Local Registration:  Once the physician is within 2.5 cm of the target, the local registration 
feature can be launche d. If desired, the physician selects the launch button on the screen to 
initiate the local registration process. The purpose of local registration is to account for CT-to -
body divergence. CT-to -body divergence exists where the patient’s anatomy does not perfectly 
align with the three -dimensional CT. Because the inhale level during the CT scan is different 
than during the procedure, the lung’s volume and shape are different. Other factors resulting in deformation or divergence from the original CT may include the presence and push by the 
bronchoscope or catheter, airway muscle’s reaction to sedation or anesthesia, a different 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 25 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  patient position, bed curvature, and anatomical changes. The software adjusts for this as much 
as possible during the initial registration procedure in step 3 by using an algorithm to perform a 
best fit alignment to the entire patient’s lungs. Since it is a best fit algorithm, some deviation 
between the model and actual anatomy can still exist and is called CT-to -body divergence.  
6. The local registration process focuses on a small region of interest around the target and 
refines the three -dimensional  model based on the fluoroscopic image data. This takes into 
consideration any changes in the patient positioning or other changes compared to the CT 
scan. Because the data is taken at the time of the procedure and covers a specific region of the 
lung, the system can create a more precise model around the target thus minimizing local CT-
to-body divergence.  
7. When the local registration feature is selected, the software guides the physician through the 
following steps: 
a. Setup  
b. Image capture using the fiducial marker board to determine angle  
c. Catheter and target marking 
d. Confirmation of catheter and target marking  
e. Once the physician has confirmed the catheter and target marking, the local registration 
feature is exited, the catheter position is updated based on the local registration, and the ENB procedure continues exactly as in the predicate by finalizing the navigation to 
the target.  The physician may also choose to disregard the update and revert to the 
previous (initial) registration or to repeat the local registration feature.  
8. End Procedure :  Once the physician has completed navigation and performed any additional 
fiducial marker placement or biopsies, the extended working channel is removed and the 
procedure completed.  
7.8. Product Training Requirements  
Only a qualified bronchoscopist (i.e., physician) may navigate with the superDimension ™ navigation 
system.  A clinician, under the direct supervision of th e bronchoscopist, may assist in the navigation 
system setup and provide care to the patient during the ENB procedure. This may be a hospital or clinic employee that has received system training.  
In order to use the local registration feature, a service representative must visit the facility and verify 
that there is a compatible fluoroscope, attach the fiducial marker board, install software, and ensure 
that the system performs as intended. Once set up, the module is used during a standard procedure when th e locatable guide is within 2.5 cm from the target.  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 26 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Each investigator participating in the clinical trial and the associated clinical study staff will receive 
training on the clinical protocol, as well as the ENB procedure utilizing the superDimension™ nav igation 
system v7.2. Physicians must demonstrate proficiency with the superDimension™ navigation system 
v7.2. 
7.9. Product Receipt and Tracking  
All products used in this study will be commercially available, and therefore do not require receipt and 
tracking inf ormation to be collected. This does not exclude the collection of Lot and/or Serial Numbers 
for the purpose of post market vigilance activities.  
7.10.  Product Storage  
All products used will be commercially available, and are expected to be stored per the site’s standard 
practice for medical equipment.  
7.11.  Product Return  
Not applicable, all study equipment to be utilized will be commercially available . 
7.12.  Product Accountability  
Not applicable, all study equipment to be utilized will be commercially available . 
7.13.  Intended C laims  
Claims and intended performance of the study product (including aspirational claims ) to be verified by 
the study:  
• Ability to compensate for localization divergence (induced by CT -to-body divergence)  
• Ability to locally register and enhance lesion visibility 
• Provide enhanced visualization 
• Provide updated catheter position relative to the nodule once nodule location is confirmed  
8. Selection of Subjects  
8.1. Study Population 
This study will be conducted in subjects over the age of 18 undergoing elective biopsy  of lung lesions 
greater than 10 mm in diameter . Additional inclusion/exclusion criteria are listed below.  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 27 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  8.2. Subject Enrollment  
This study will enroll up to 50 subjects meeting the inclusion criteria, with a maximum of 25 subjects per 
site. Up to 5 clinical sites in the United States are planned. 
Subjects meeting the inclusion/exclusion criteria below will be enrolled. Following signing the  informed 
consent form ( ICF), the point of enrollment is defined as the entry of the first locatable guide . 
The ENB procedu re will be performed per the System User Manual, applicable product instructions for 
use (IFU) and the institution’s standard practice. Subjects will be considered  for the study if they meet 
specified inclusion criteria and none of the exclusion criteria. The criteria for enrollment must be 
followed explicitly . 
8.2.1.  Roll-in Subjects  
A maximum of five roll -in cases will be allowed per investigator. The purpose of the roll-in cases is to 
provide consistency in the physician user base within the study and optimize procedural methods. Roll -
in subjects will be considered study participants  and will complete all protocol-required procedures and 
exams. An interim analysis will be conducted after the completion of roll-in enrollment to evaluate study 
workflow and data validity. The protocol will be amended if necessary.  
8.3. Inclusion Criteria  
1. Subject presents with lung lesion(s) greater than 10 mm in diameter amenable to evaluation by 
ENB at the time of evaluation 
2. Lesion is intended to be biopsied by the participating investigator  
3. Subject is willing and able to provide informed consent to participate in the study 
4. Subject is a candidate for an elective ENB procedure 
5. Subject is over the age of 18  
8.4. Exclusion Criteria  
1. Central lesions  that are not visible endobronchially  or could be  reached by a flexible 
bronchoscope or endobronchial ultrasound ( EBUS ) without the utilization of ENB  
2. Lesions within 10  mm of the diaphragm 
3. The subject is unable or unwilling to comply with study follow -up schedule  
4. The subject has participated in an investigational drug or device research study within 30 days 
of enrollment that would interfere with this study  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 28 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  5. Female subjects who are pregnant or nursing as determined by standard site practices   
9. Study Procedures  
Below is a description of the procedures that the subject will undergo during the clinical study. 
9.1. Schedule of Events  
Variables to be collected,  follow-up visit schedule, and tests to be performed at each visit are described 
in Table 1 below. 
Table 1. Schedule of Events  
 Baseline 
(Day - 30 to Day 0)  During  and 
immediately post -
procedure  
(Day 0)  7 days Post -
Procedure  
(window = 4 -7 days)  
Informed consent  X   
Eligibility criteria  X   
Demographics  X   
Medical history  X   
Procedural information  X  
Lesion characteristics  X X  
Adverse event assessment   X X 
Biopsy results  X X 
 
  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 29 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  9.1.1.  Overview of Study Procedures  
Figure 6 . Procedure Steps  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 30 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  9.2. Subject Screening  
A baseline visit will be performed within 30 days prior to the scheduled pr ocedure to assess study 
eligibility. Consented subjects will be considered for the study if they meet specified inclusion criteria 
and none of the exclusion criteria. The criteria for enrollment must be followed explicitly.  
Subjects who provide study consent, but then are determined to be ineligible prior to the ENB 
procedure will be considered Screen Failures and will not require additional study follow-up visits. The 
reason for the Screen Failure will be clearly documented on the applicable electronic cas e report forms 
(eCRFs) . Screen Failures will not be counted towards the number of study subjects. 
9.3. Prior and Concomitant Medications  
All prior and concomitant medications should be managed according to standard -of-care.  
9.4. Subject Consent  
Subjects will be app roached to obtain written informed consent prior to any institution non -standard -of-
care assessments or study specific data being collected. The purpose of the study and the benefits and risks of participating in the study will be explained to the subject and the consent process must be 
documented accordingly.  
Subjects will be informed that their participation in this study is voluntary and that they may refuse to participate or discontinue from the study at any time. Additionally, subjects will be informed that 
despite signing informed consent, the screening assessments may demonstrate the subject is not a 
suitable candidate for the study and may be withdrawn. Subjects will be given the opportunity to ask the 
investigator questions so that they are adequate ly informed about the research.   
After being informed of the nature of the study, subjects who agree to study participation must sign a 
written ICF that has been approved by the appropriate Institutional Review Board (IRB) or Ethics 
Committee (EC) of the respective clinical site. A copy of the signed ICF must be provided to the subject.  
For this study, the subject must sign and date the ICF themselves. The use of Legally Authorized 
Representatives, Healthcare Proxies or any other means of representation will not be permitted.  
If new information becomes available that may affect a subject’s decision to continue to take part in the study, this information will be discussed with the subject.  
The principal investigator or his/her authorized designee must conduct  the informed consent process.  
9.5. Randomization and Treatment Assignment  
Not applicable. There are no treatment arms or randomizations required for this study.  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 31 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  9.6. Medication Compliance  
Not applicable. There are no required medications or medication protocols fo r this study.  
9.7. Assessment of Efficacy  
9.7.1.  Baseline  
The following assessments will be performed within 30 days prior to the scheduled ENB procedure:  
• Signed informed consent  
• Eligibility criteria  
• Subject  demographics  
• Medical history  
9.7.2.  Procedure Day 
The following procedures and assessments will be performed on the day of the index procedure (Day 0):  
• Lesion characteristics  (e.g., size, location, morphology)  
• Procedural informatio n (e.g., technical success, procedure time, biopsy tools, primary and 
secondary endpoints ). 
9.7.3.  Procedure Details  
Details of the index procedure are given below (see also Figure 6 ). 
1. Begin ENB per standard practice. 
2. Complete automatic registration and navigate to a position that is within 2.5 cm of the target 
index lesion. 
3. Lock LG in place and c onduct l ocal registration with Fluoroscopic Navigation Technology 
(without moving the catheter). 
4. Complete a CBCT scan to document the correct location  (prior to any movement of the LG) .  
5. Complete navigation and position the  catheter as appropriate based on the local registration 
correction . 
6. Conduct a s econd local registration.  
7. Conduct a second CBCT. 
8. Advance the first biopsy tool . 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 32 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  9. Once in place to biopsy, capture fluoroscopy  video sweep with a tool in place (Fluoro “Tool i n 
Lesion”). “In Place” is intended to mean in the location at which tissue sampling would occur . 
10. Complete a CBCT scan to confirm that the biopsy tool is accurately positioned in three 
dimensions within the lesion ( CBCT “Tool in Lesion”).  
11. If available, rad ial endobronchial ultrasound (rEBUS) may be used to reconfirm the location  
12. Complete biopsy sampling  per standard size practices . 
13. Complete lymph node sampling per standard site practices.  
9.7.4.  Study Completion  
Subjects will complete the study at the completion o f the 7-day  post -procedure visit . No additional care 
will be provided to study subjects after completion of the study with respect to this clinical investigation plan ( CIP). Standard of care should continue.  The reporting window for the 7 -day follow -up is 4-7 days.  
9.8. Assessment of Safety  
Adverse events will be collected after the ENB index procedure has been initiated (defined as introduction of the locatable guide or extended working channel into the subject). Adverse events will be collected immediately pos t-procedure  and at 7-day  post -procedure visit , with a window of 4-7 days 
post -procedure for the 7-day phone call . 
The following safety endpoints will be evaluated in all enrolled subjects. These events will be evaluated 
for their relationship to the study device and study procedure, and classified according to CTCAE Version 
5. 
• Incidence of all pneumothorax related to ENB index procedure  
• Incidence of CTCAE Grade ≥2 pneumothorax related to the ENB index procedure  
• Incidence of all bronchopulmonary hemorrhage related to ENB index procedure 
• Incidence of CTCAE Grade ≥2 bronchopulmonary hemorrhage related to the ENB index 
procedure  
• Incidence of CTCAE Grade ≥4 respiratory failure related to ENB index procedure   
In addition to the Safety Endpoints described above, all Adverse Events related to the superDimension™ 
navigation system, associated tools, or ENB procedure as described in  Section  11. 
9.9. Recording Data  
This study will utilize an eCRF. The eCRF will be used to capture the required d ata elements. Medical and 
study records, rather than eCRFs, will serve as the source documentation. 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 33 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  9.10.  Deviation Handling  
The Principal Investigator must make every effort to follow the CIP, unless the deviation is necessary in 
an emergent situation to protect the rights, safety and/or wellbeing of the subject. Deviations from the 
CIP will be collected on a Protocol Deviation CRF and reviewed with the Principal Investigator to ensure compliance.  
The investigator must notify Medtronic and the reviewing IRB/EC of any deviation from the 
Investigational Plan when specific to the protection of the life or physical well- being of a subject in an 
emergency . Such notice must be given as soon as possible, but in no event later than five (5) working 
days after the emergency has occurred.   
If a pattern of non-c ompliance is noted , the study manager will determine the course of action to take, 
such as root cause, review relevant CIP procedures and as applicable retrain and verify understanding of the issue in question. This will be documented in the Study Master Files. In the case of repeated or 
serious non -compliance, the Sponsor reserves the right to disqualify the offending site. 
9.11.  Subject Withdrawal or Discontinuation  
Subjects may voluntarily withdraw themselves from the study if they no longer wish to have their study related information used. Additionally, the Principal Investigator may withdraw or choose not to enroll a 
subject if they feel they do not meet the CIP defined Inclusion and Exclusion Criteria or if it is in the best 
medical interest of the subject in question.  
In cases of voluntary subject withdrawal, all data collected from the time of Informed Consent to the 
time of Voluntary withdrawal may be used. Additionally, subjects who withdraw or discontinue will no t 
be replaced. Enrollment will continue as per CIP definitions up to the predefined maximum number of subjects.  
The reason for study exit of all enrolled subjects will be documented on the applicable electronic case 
report form (eCRF). In the event the subject withdraws consent during the study, the date of withdrawal 
will be documented. If the study investigator voluntarily removes a subject from further study 
participation, supporting documentation must be in place for the rationale and date of removal. E very 
attempt will be made to contact subjects who are noncompliant. Subjects will be considered lost to 
follow-up once the following steps have been taken:  
• Three phone calls should be made to the subject. Each attempt should be clearly documented in 
the so urce documents and the response or lack thereof should be captured.  
• If there is no response to the phone calls, then certified letter should be written to the subject. A 
copy of the letter should be retained in the subject’s source document.  
• After a period  of one (1 ) week following completion of the above actions, the subject will be 
considered Lost to Follow -up. The sponsor should be notified and the Study Exit form should be 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 34 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  completed.   
10. Risks and Benefits  
10.1.  Potential Risks  
All devices utilized in this study  are commercially available. There are no anticipated risks related to 
inclusion of subjects in this clinical study above and beyond anticipated risks related to any ENB 
procedure. All records identifying the subject will be kept confidential and, to the extent permitted by 
the applicable laws and/or regulations, will not be made publicly available. Subject names will be kept confidential.  
Addition of the Fluoroscopic Navigation  Technology  to the superDimension™ Navigation System is not 
expected to increas e the risk of the device beyond the risks previously reported for superDimension™ 
Navigation System v7.1. Potential risks of the use of the superDimension™ Navigation System for ENB 
procedures have been evaluated in the superDimension ™ navigation system v7 .2 Use Failure Modes and 
Effects Analysis (UFMEA ; DHA00036 Rev B, with unchanged risks from DHA00027 Rev I ), as well as in the 
NAVIGATE Clinical Trial Medical Device Reporting ( MDR ) Reportable Event Trend & Risk Analysis Report 
for the superDimension™ Navi gation System Version 7.2 (DGR00462, Effective28-Sep-2017).  
10.1.1.  
Summary MDR Reportable Event Trend & Risk Analysis Report  
The NAVIGATE clinical study (study number [STUDY_ID_REMOVED]) first subject  enrollment occurred on April 16, 
2015. The objective of the study is  to evaluate outcomes following electromagnetic navigation 
bronchoscopy (ENB) procedures using the superDimension™ navigation system.39 
An analysis was performed o n the MDR reportable events associated with the NAVIGATE study to 
determine how this information relates to the superDimension™ navigation system v 7.2. In this analysis 
the MDRs associated with NAVIGATE were reviewed for any notable trends and new adverse effects. 
The reporting period for the analysis ranged from April 2015 through July 2017. During this time there have been 291 reportable events reported by Covidien llc to the FDA. This includes 130 deaths, 3 
malfunctions, and 158 serious injuries. The maj ority of deaths were determined to be primarily related 
to the patient’s condition with no allegations against a Covidien llc Interventional Lung Solutions (ILS) 
device. The overall adverse event reporting rate for the ILS group during the time period was 1.16% (including the MDRs associated with NAVIGATE).  
Risk management procedures and supporting documentation were updated to align adverse effects and occurrence rates observed in the NAVIGATE MDR data. Furthermore, a field experience analysis was performe d for the superDimension™ navigation system v 7.2 to determine any additional design inputs 
during development.  
A paper  published in April 2017 documents the results of the first 1,000 subjects enrolled in the 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 35 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  NAVIGATE study after one -month follow -up.37 The interim data provides an early look at typical patient 
and l esion characteristics and procedural standard -of-care. Data demonstrated low adverse event rates 
in a generalizable population across diverse practice settings.  
Overall, no notable trends were identified based on the analysis of the NAVIGATE study MDRs. Th e 
report summarizing the first 1,000 subjects at one- month follow -up further demonstrates a safe patient 
profile for the superDimension™ navigation system.37 The data generated from the NAVIGATE study was 
taken into consideration and incorporated during the development of the superDimension™ navigation 
v7.2 system.  
In the majority of cases, the root cause could not be determined as the device was either not returned 
for analysis or no issues were found during investigation (127). Some cases were attributed to the ENB procedure (15) and patient condition (1) with no a llegations against ILS devices or were attributed to 
non-ILS devices (11).  
The most common serious injury reported included pneumothorax (72), bleeding (38), and medical 
complications (31). Pneumothorax and bleeding are known complications associated with  
electromagnetic navigation systems.  A further breakdown of adverse events by the subject device and 
investigation results is provided below in Table 2. 
Please refer to the most current version of the Reportable Ev ent Trend & Risk Analysis Report for 
additional information. 
 
 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 36 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Table 2. Event Type by Device  
Subject Device  Event Type  Internal Investigation Results  Total  
System Console  Pneumothorax Inconclusive – no anomalies identified (28)  
40 Related to procedure (4)  
Related to non -superDimension Tool (7)  
Investigation in process (1)  
Bleeding Inconclusive – no anomalies identified (14)  
19 Related to non -superDimension Tool (4)  
Patient Condition (1)  
Pneumomediastinum  Inconclusive – no anomalies identified (3)  3 
Medical 
Complication Inconclusive – no anomalies identified (22)  
27 
Related to procedure (5)  
Respiratory Complication Inconclusive – no anomalies identified (11)  
14 
Related to procedure (3)  
GenCut Core  
Biopsy Tool  Pneumothorax Inconclusive – no anomalies identified (1)  
2 
Related to procedure (1)  
Bleeding Inconclusive – no anomalies identified (2)  
4 Related to procedure (1)  
Inconclusive – no device information provided (1)  
Biopsy Forceps  Pneumothorax Inconclusive – no anomalies identified (9)  9 
Bleeding Inconclusive – no anomalies identified (2)  
7 Inconclusive – no device information provided (3)  
Investigation in process (2)  
Biopsy Needle Pneumothorax Inconclusive – no anomalies identified (5)  
7 Inconclusive – no device information provided (1)  
Investigation in process (1)  
Bleeding Inconclusive – no anomalies identified (4)  5 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 37 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Table 2. Event Type by Device  
Subject Device  Event Type  Internal Investigation Results  Total  
Inconclusive – no device information provided (1)  
Medical 
Complication Inconclusive – no a nomalies identified (1)  1 
Cytology Brush  Pneumothorax Inconclusive – no anomalies identified (7)  
12 
Inconclusive – no device information provided (5)  
Bleeding Inconclusive – no anomalies identified (1)  
3 
Inconclusive – no device information provided (2)  
Extended 
Working 
Channel  Pneumothorax Related to procedure (1)  1 
Medical Complication Inconclusive – no anomalies identified (2)  
3 
Inconclusive – no device information provided (1)  
Fiducial Marker  Pneumothorax Inconclusive – no anomalies i dentified (1)  1 
  Total  158 
10.1.2.  Study- related Imaging 
There are risks associated with the use of x -ray fluoroscopy and CBCT imaging for this study.  
A milliSievert (mSv) is a unit of radiation dose . The average  effective radiation dose during a typical 
bronc hoscopy procedure with fluoroscopic guidance is approximately 0.5 mSv40 up to 2 mSv per scan. 
The typical radiation dose from a chest CBCT scan is estimated a t 0.98-1.15 mSv .41 Up to approximately 
3 fluoroscopy sweeps and 3 CBCT scans will be conducted during the study procedure. Thus, the total 
radiation exposure from this study is estimated at up to 9-10 mSv. It should be noted that radiation dose 
will vary based on the type of imaging system used and the size of the patient.  
For comparison, the average dose from natural sources of radiation is approximately  3 mSv per year 
from natural background radiation, such as radon and cosmic rays . In higher elevation areas the 
background exposure can be as high as 10 mSv per year. The annual allowable dose for radiation 
workers (e.g., x-ray technicians) is 50 mSv.  
The probability for absorbed x -rays to induce cancer or heritable mutations leading to  genetically 
associated diseases in offspring is thought to be very small for radiation doses of the magnitude that are 
associated with CT procedures. For any one person, the risk of radiation -induced cancer is much smaller 
than the natural risk of cancer. However, the risk of harmful effects may increase if a patient is exposed 
to additional procedures that involve radiation such as x-rays or additional CT scans required during 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 38 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  standard of care.  
10.2.  Potential Benefits  
Outside of the normal ENB procedure, the study may or may not be of benefit to the study subjects. The 
data collected from this study will help to collect new information on the accuracy of the Fluoroscopic 
Navigation  Technology feature and future system enhancements. 
10.3.  Risk-Benefit Rationale  
Every effort will be made to minimize the risks discussed in Section 10.2, as these risks are standard for 
this procedure. There will be minimal change to the execution of the ENB procedure as it relates to the 
planning, ENB guidance of associated procedural biopsy tools or method of sampling. It is more likely 
that the addition of the fiducial board will improve visibility and provide a reference of measurement for areas of interest.  
Additional design elements to reduce risk and burden to the subject are described in  Section 6.2. 
11. Adverse Events and Device Deficiencies  
11.1.  Definitions /Classifications  
Adverse event definitions used in this study are based on ISO 14155:2011 (Clinical Investigation of 
Medical Devices for Human Subjects -- Good Clinical Practice ; 
https://www.iso.org/obp/ui/#iso:std:iso:14155:ed-2:v1:en ), which is aligned with MEDDEV 2.7/3 
Revision 3, May 2015 (Guidelines on Medical Devices, Clinical Investigations: Serious Adverse Event Reporting).   
Adverse events will be collected after the point of enrollment  (defined as introduction of the locatable 
guide into the subject). Adverse events ( AEs) will be monitored until a subject completes the study. Any 
unresolved procedural or device related events that are still ongoing past study exit will be monitored by 
the physician per their institutional standard of care.  
In addition to the Safety Endpoints described in Section 5.4 , all Adverse Events related to the 
superDimension™ navigation system, associated tools, or ENB procedure. 
Anticipated adverse events are listed in Section 10.1 . 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 39 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  11.1.1.  Adverse Event (AE)  
An Adverse Event is any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including abnormal laboratory findings) in subjects whether or not related to the 
investigational medical device.  
NOTE 1:  This definition includes events relat ed to the superDimension™ Navigation System v7.2 with 
Fluoroscopic Navigation Technology  and all superDimension™ tools and accessories.  
NOTE 2:  This definition includes events related to the procedures involved, including bronchoscopy and 
sedation.  
Events  occurring in users or other persons related to the medical device will not be collected for the 
purposes of this study.  
11.1.2.  Serious Adverse Event (SAE)  
For the purposes of this study, a Serious Adverse Event is an adverse event that has 
1. Led to death,  
2. Led to serious deterioration in the health of the subject, that either resulted in  
a. A life -threatening illness or injury, or  
b. A permanent impairment of a body structure or a body function, or  
c. In-patient or prolonged hospitalization, or  
d. Medical or surgical interventi on to prevent life-threatening illness or injury or 
permanent impairment to a body structure or a body function . 
NOTE 1: This includes device deficiencies that might have led to a serious adverse event  if a) suitable 
action had not been taken or b) intervention had not been made or c) if  circumstances had been less 
fortunate. These are handled under the SAE reporting  system.  
NOTE  2: Planned hospitalization for a pre -existing condition, or a procedure required by the clinical 
investigational plan, without s erious deterioration in health, is not considered a serious adverse event.  
11.1.3.  Adverse Device Effect (ADE) 
An Adverse Device Effect is an adverse event related to the use of an investigational medical device . 
NOTE 1:  This definition includes adverse events re sulting from insufficient or inadequate instructions for 
use, deployment, implantation, installation, or operation, or any malfunction of the investigational medical device.  
NOTE 2:  This definition includes any event resulting from use error or from intentional misuse of the 
investigational medical device.  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 40 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  11.1.4.  Serious Adverse Device Effect (SADE)  
A Serious Adverse Device Effect is an adverse device effect that has resulted in any of the consequences 
characteristic of a serious adverse event.  
11.1.5.  Unanticipated Serious Adverse Device Effect (USADE) 
An Unanticipated Serious Adverse Device Effect (USADE) is defined as serious adverse device effect which by its nature, incidence, severity or outcome has not been identified in the current version of the risk analysis rep ort. 
11.1.6.  
Device Deficiency  
Inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety or 
performance . 
Note: Device deficiencies include malfunctions, use errors, and inadequate labelling.  
11.1.7.  Adverse Event Relationship Cl assification  
Causality assessments define the relationship between the use of the medical device (including the procedure) and the occurrence of each adverse event. During causality assessment activity, clinical 
judgment shall be used and the relevant docu ments, such as the MDR  Reportable Event Trend & Risk 
Analysis Report shall be consulted, as all the foreseeable serious adverse events and the potential risks 
are listed and assessed there. The presence of confounding factors, such as concomitant 
medicatio n/treatment, the natural history of the underlying disease, other concurrent illness or risk 
factors shall also be considered.  
Each AE and SAE will be classified according to five different levels of causality. The following definitions 
will be used to  assess the relationship of the serious adverse event to the investigational medical device, 
accessory devices, or procedures:  
• Not related:  Relationship to the device or procedures can be excluded when:  
o the event is not a known side effect of the product category the device belongs to or of 
similar devices and procedures  
o the event has no temporal relationship with the use of the investigational device or the 
procedures;  
o the serious event does not follow a known response pattern to the medical device (if the re sponse pattern is previously known) and is biologically implausible;  
o the discontinuation of medical device application or the reduction of the level of 
activation/exposure - when clinically feasible – and reintroduction of its use (or increase 
of the level of activation/exposure), do not impact on the serious event;  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 41 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  o the event involves a body- site or an organ not expected to be affected by the device or 
procedure;  
o the serious event can be attributed to another cause (e.g. an underlying or concurrent 
illness/ clinical condition, an effect of another device, drug, treatment or other risk 
factors);  
o the event does not depend on a false result given by the investigational device used for diagnosis, when applicable;  
o harms to the subject are not clearly due to use error;  
o In order to establish the non -relatedness, not all the criteria listed above might be met 
at the same time, depending on the type of device/procedures and the serious event.  
• Unlikely: T he relationship with the use of the device seems not relevant and /or the event can be 
reasonably explained by another cause, but additional information may be obtained.  
• Possible :  The relationship with the use of the investigational device is weak but cannot be ruled 
out completely. Alternative causes are also possible (e.g. an underlying or concurrent illness/ 
clinical condition or/and an effect of another device, drug or treatment). Cases were relatedness cannot be assessed or no information has been obtained should also be classified as possible.  
• Probable :  The relati onship with the use of the investigational device seems relevant and/or the 
event cannot reasonably be explained by another cause, but additional information may be obtained. 
• Causal relationship: The serious event is associated with the investigational dev ice or with 
procedures beyond reasonable doubt when:  
o the event is a known side effect of the product category the device belongs to or of similar devices and procedures; 
o the event has a temporal relationship with investigational device use/application or procedures;  
o the event involves a body- site or organ that  
o the investigational device or procedures are applied to; 
o the investigational device or procedures have an effect on;  
o the serious event follows a known response pattern to the medical device (if the response pattern is previously known);  
o the discontinuation of medical device application (or reduction of the level of activation/exposure) and reintroduction of its use (or increase of the level of activation/exposure), impact on the serious event (when clinically feasible);  
o other possible causes (e.g. an underlying or concurrent illness/ clinical condition or/and an effect of another device, drug or treatment) have been adequately ruled out;  
o harm to the subject is due to error in use;  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 42 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  o the event depends on a  false result given by the investigational device used for 
diagnosis, when applicable; 
o In order to establish the relatedness, not all the criteria listed above might be met at the 
same time, depending on the type of device/procedures and the serious event. 
Events will be distinguished between the serious adverse events related to the device and those related 
to the procedures (any procedure specific to the clinical investigation). An adverse event can be related 
both to procedures and the device. Complications of procedures are considered not related if the said procedures would have been applied to the patients also in the absence of device use/application.  
In some particular cases the event may be not adequately assessed because information is insufficient 
or contradictory and/or the data cannot be verified or supplemented. The sponsor and the Investigators 
will make the maximum effort to define and categorize the event and avoid these situations. Where the 
sponsor remains uncertain about classifying the serious event, it should not exclude the relatedness and 
classify the event as “possible” . 
11.1.8.  
Adverse Event Outcome Classification  
Outcome of the event will be defined according to the following:  
• Fatal :  If death was possibly, probably, or causally related to the event  
• Not recovered / not resolved:  Subject has exited the study and the AE is ongoing and not 
expected to resolve  
• Recovered / resolved:  The event has fully resolved prior to study exit  
• Recovered / resolved with sequelae:  The event has resolved prio r to study exit, but retained 
pathological conditions resulting from the prior disease or injury  
• Recovering / resolving:  T he subject has exited the study and the AE is ongoing but expected to 
resolve 
• Unknown :  The subject has exited the study and the AE outcome is unknown  
11.2.  Reporting of Adverse Events  
Assessment of the occurrence of an AE will be based on changes in the subject’s physical examination, 
laboratory results, and/or signs and symptoms. AEs will be monitored until a subject completes the study. A ny unresolved procedural or device related events that are still ongoing past study exit will be 
monitored by the physician per their institutional standard of care. AEs will be documented in the applicable source documentation and reported on an AE eCRF. To the extent possible, the event to be 
recorded and reported is the event diagnosis as opposed to event outcome (e.g., death) or symptoms 
(e.g., fever, chills, nausea and vomiting in the presence of a clinically diagnosed infection is to be 
reported as in fection only).  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 43 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  The following should not be considered an AE:  
• A condition requiring a preplanned procedure unless the condition worsened since enrollment  
• A preexisting condition found as a result of screening, unless the condition has worsened since 
enrollm ent. 
For purposes of this protocol, the following occurrences are considered to be expected observations 
following bronchoscopy procedures (primarily associated with anesthesia) and will not be considered 
AEs, as long as the event is not associated with si gnificant sequelae, does not prolong hospitalization, 
and responds to standard medical therapy:  
• procedure transient nausea determined to be procedure related and resolving within 4 days 
after the procedure  
• Post procedure transient emesis determined to be  procedure related and resolving within 3 
days after the procedure  
• Post procedure constipation, determined to be procedure and/or medication related  
• Post procedure pain that the study investigator considers common and expected post procedure  
All responses  to the above events that require treatment beyond the institution’s standard procedures 
will be reported as AEs.  
11.2.1.  Notification to Authorities  
The following events are generally considered reportable during the course of this study and should be 
reported within the timeframes outlined in Table 3: 
• any AE or SAE  
• any Device Deficiency  
• new findings/updates in relation to already reported events  
 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 44 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  Table 3. Reporting of Adverse Events  
Type  Report to Reporting Timeframe (from time of 
learning of event)  
Device Deficiency  Sponsor  Not to exceed  10 working days   
AE Sponsor  Not to exceed  10 working days  
IRB/EC  Per IRB/EC  reporting requirements  
SAE Sponsor  Not to exceed 10 working days  
IRB/EC  Per IRB/EC  reporting requirements  
Events will be reviewed by sponsor or designee to determine any reporting obligations to National 
Competent Authorities and IRB/EC.   
Any Adverse Event will be recorded on the Adverse Event CRF.  
12. Data Review Committees  
There will be no Data Mo nitoring Committee, Clinical Events Committee or Adverse Events Advisory 
Committee needed for this post -market feasibility study . 
13. Statistical Design and Methods  
All statistical analyses will be performed using Statistical Analysis System (SAS) for Windows (version 9.2 
or higher, SAS Institute Inc. Cary, NC) or other widely accepted statistical or graphical software.   
Descriptive statistics will be used to present the data and to summarize the results. Continuous variables 
will be summarized with number of s ubjects (n), mean, standard deviation, median, and ranges.  
Categorical variables will be summarized by frequencies and percentages . 
The sample size of this feasibility study is not based on power calculations of a statistical hypothesis test.  
The following endpoints will be evaluated in Technically Successful cases (those with local registration 
complete) : 
• Primary Endpoint:   The measured ability of the superDimension ™ Navigation System v7.2 with 
Fluoroscopic Navigation Technology to place the center of the virtual navigation target (green 
ball) on the intended target lesion as confirmed by CBCT.  
• Secondary Endpoint:  Percentage of cases in which the intended lesion is correctly identified (as 
opposed to a non -target lesion or normal lung tissue) as indicated by the system software.  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 45 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  • Secondary Endpoint:   Relational Accuracy in cases in which the Intended lesion is targeted.  
All other endpoints and safety outcomes will be evaluated in all enrolled subjects.  
The following analyses will be conducted: 
• Interim Analy sis:  Will be conducted after the first 5 procedures have been completed for the 
purpose of evaluating workflow and data validity. 
• Final Analysis : Will be conducted after all subjects have completed the procedure for the 
purpose of evaluating the primary and secondary endpoints.  
There are no pre-planned subgroup analyses. Any post -hoc subgroup analyses will be exploratory in 
nature for the purpose of evaluating the safety and performance of the study device under various 
clinical conditions. 
Due to the post-market and observational nature of the study, no imputation is planned for missing data 
in the primary and secondary endpoints, if any. All available data from enrolled subjects will be 
reported.  
A detailed Statistical Analysis Plan (SAP) will be prepared prior to data analysis.  
Any deviations from this analysis plan will be documented in the final clinical study report.  
14. Ethics  
14.1.  Statement(s) of Compliance  
This clinical investigation will be conducted in accordance with the ethical principles that have their 
origin in the Declaration of Helsinki, as well as with ISO 14155:2011 (Clinical Investigation of Medical 
Devices for Human Subjects – Good Clinical Practice) and the International Conference on 
Harmonisation (ICH) of Technical Requirements For Registra tion of Pharmaceuticals For Human Use, ICH 
Harmonised Tripartite Guideline for Good Clinical Practice E6 (R1). The principles of the Declaration of 
Helsinki have all been implemented by means of the subject  informed consent process, EC approval, 
study trai ning, clinical study registration, preclinical testing, risk benefit assessment, and publication 
policy.  
Pediatric, legally incompetent, or other vulnerable subjects are not eligible for the study.  
The clinical investigation will not begin until all nece ssary approvals/favorable opinions are obtained 
from the appropriate IRB/EC s or regulatory authority, as appropriate. Should an IRB/EC  or regulatory 
authority impose any additional requirements, they will be followed.  
Information regarding the study and study data will be made available via publication on clintrials.gov.  
Additionally, the results of this study will be submitted for publication in an appropriate journal. 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 46 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  No insurance or compensation will be provided to study subjects . 
Medtronic maintains appropriate clinical study liability insurance coverage as required under applicable 
laws and regulations and will comply with applicable local law and custom concerning specific insurance 
coverage. If required, a clinical study insurance statement/certificate will be provided to the IRB/EC . 
15. Study Administration  
15.1.  Monitoring  
Site visits will be conducted by an authorized Medtronic representative to inspect study data, subjects’ medical records, and CRFs in accordance with current ICH GCPs and the respective loc al and national 
government regulations and guidelines (if applicable).  The study investigator and the investigating site 
will permit authorized clinical research personnel and clinical monitors from Medtronic and/or designee(s) employed by Medtronic to rev iew completed CRFs, IRB decisions, and Investigator, clinical 
site records, and facilities relevant to this study at regular intervals throughout the study per the monitoring plan. Additionally, subject charts and clinical records will be requested and rev iewed so that 
protocol adherence and source documentation can be verified.  
The accuracy and quality of the data obtained from the investigator and maintained by the Sponsor will 
be confirmed through a structured program of clinical field auditing and internal review detailed in the monitoring plan. In instances where data protection regulations prohibit the direct examination of 
hospital records by the study Sponsor or designee(s), the Investigator will cooperate in a system of 
source data verification wit h the Sponsor. Monitoring may be performed with in person visits or 
remotely, when applicable.  
To ensure the rights, safety, and welfare of study subjects are being maintained, the monitor will maintain assurance that all study staff are trained on the CI P and use of the study devices.  If the monitor 
discovers that an investigator is not complying with the signed Clinical Trial Agreement , the 
investigational plan, applicable laws, or any conditions of approval imposed by the reviewing IRB or Competent Auth ority, the monitor will report to the Sponsor and take such steps necessary to promptly 
secure compliance. If compliance cannot be secured, the investigator’s participation in the investigation 
may be terminated.   
Because there are no required medications for this study or other subject -generated reporting 
requirements, monitoring of subject compliance is not applicable to this study.  
For the purpose of this study, 100% of Endpoint Related data will be monitored. This is intended to include all data related to the calculation of the Primary or a Secondary Endpoint, as well as any data 
related to a Safety Event.  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 47 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  15.2.  Data Management  
This study will utilize an electronic database and eCRF. All data requested on the eCRF are considered 
required. Data points not collected and/or recorded will be considered deviations unless otherwise 
specified. No data points will be collected directly on the CRF.  
In order to accurately collect all information, subject worksheets may  also be provided for study specific 
data (specific procedure data points, etc.) not found in the medical records and will be considered the 
source document.  
The Principal Investigator must ensure the accuracy and completeness of the recorded data and then 
provide his/her electronic signature on the appropriate CRFs.  The Investigator’s signature for specific 
CRFs will be documented in compliance with local regulations.  Changes to data previously submitted to 
the sponsor will require a new electronic signature by the Investigator to acknowledge/approve the changes.  
Visual and/or computer data review will be performed to identify possible data discrepancies. Manual 
and/or automatic discrepancies will be created in the Oracle remote data capture (RDC) system and will 
be issued to the site for appropriate response. The site staff will be responsible for resolving all 
discrepancies in the database.  
15.3.  Direct Access to Source Data/Documents  
The investigator(s)/institution(s) will permit inspection and  study -related monitoring, audits, IRB/IEC 
review, and regulatory i nspection(s), including direct access to source data/documents.  
15.4.  Confidentiality  
All records identifying the subject will be kept confidential and, to the extent permitted by the 
applicable laws and/or regulations, will not be made publicly available.  
Subject names will be kept confidential.  Only the subject number will be recorded in the eCRF, and if the 
subject name appears on any other document, it must be obliterated.   
Study findings stored on a computer will be stored in accordance with local data pro tection laws.  The 
subjects will be informed in writing that representatives of the sponsor, IRBs, or Regulatory Authorities may inspect their medical records to verify the information collected, and that all personal information 
made available for inspection will be handled in strictest confidence and in accordance with local data 
protection laws.  
Subjects will also be informed that information regarding the study that does not include subject 
identifiers will be posted on www. clinicaltrials.gov. 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 48 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  If the re sults of the trial are published, the subject’s identity will remain confidential.  
The investigator will maintain a list to enable subjects’ records to be identified.  
15.5.  Liability  
Medtronic maintains appropriate clinical study liability insurance coverage as  required under applicable 
laws and regulations and will comply with applicable local law and custom concerning specific insurance 
coverage. If required, a clinical study insurance statement/certificate will be provided to the IRB.   
15.6.  CIP Amendments  
Should any amendment to the CIP be required, the CIP Author will collect and review all proposed updates.  These will be incorporated as needed and approved per the CIP Approval Process.  
15.7.  Record Retention 
The investigator will maintain the records of the study including all pertinent correspondence, the CIP  
with any/all amendments, all correspondence with and approval from the IRB, the clinical investigation 
agreement, the Clinical Trial Agreement , individual subject records, and signed ICFs. Subject files and 
other source data must be kept for a period of not less than two (2) years after the date on which this 
investigation is terminated or completed.   
Records may need to be maintained by the study investigator for a longer duration if national 
regulations require or if agreed to in writing with Medtronic.  All data and documents should be made 
available if requested by relevant authorities.   
15.8.  Publication and Use of Information 
The Medtronic Publication and Authorship Policy is aligned with the International Committee of Medical 
Journal Editors (ICMJE) recommendations (www.icmje.org). The Sponsor will seek to publish, in 
appropriate peer -reviewed journals and scientific conferences, results of clinical studies where human 
subjects are involved, regardless of outcome. Wh ile study results are owned by the Sponsor, all data on 
which a publication is based will be made available to all authors as required for their participation in the publication process. Furthermore, data may be published or used by study investigators pro vided 
that such publication or use is in accordance with this protocol, the Medtronic Publication and 
Authorship Policy, and the Clinical Investigation Agreement. Investigators must submit a copy of all 
manuscripts and/or abstracts to the Sponsor for revie w and comment 30 days prior to planned 
submission. Medtronic acknowledges that its right to review and comment shall relate solely to  the 
proprietary, licensing, and/or confidential rights Medtronic may have in such proposed publication, rather than whether such results and/or opinions are favorable to Medtronic.   

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 49 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  The publication of substudies, post -hoc analyses, regional results, or single-center experiences based on 
multicenter clinical studies should not precede that of the primary multicenter publication, and should 
cite the primary publication whenever possible, as required by specific journal and scientific meeting 
guidelines.  
Medtronic involvement in a publication (e.g., funding of the study; sponsor of the study; collection, 
analysis, and interpretation of data; professional writing assistance) must be disclosed according to 
journal -specific policies, submission requirements, and prevailing editorial standards, in addition to 
those specified by International Committee of Medical Journal Editors. Authors must ensure that an 
acknowledgement/disclosure statement is included in the body of the manuscript for Medtronic to 
review for accuracy. All authors must also disclose financial or personal affiliations that could be considered conflicts of interest as  per journal/conference requirements.  
To enable health care providers, payers, and patients access to the wealth of Medtronic’s research, Medtronic will report its scientific data in accordance with the principles outlined in the Guidance 
Document on Regis tration and Reporting Results of Company -Sponsored Clinical Trials , Section 801 of 
the Food and Drug Administration Amendments Act (FDAAA 801) and the Final Rule for Clinical Trials 
Registration and Results Information Submission (42 CFR Part 11, January 1 8, 2017).  
15.9.  Suspension or Early Termination 
Medtronic reserves the right to discontinue the study at any stage, with suitable written notice to the investigator, the reviewing IRB, and applicable regulatory agencies.  Similarly, the investigator may 
withdraw from the study at any time, subject to providing written notification to Medtronic 30 days 
prior to the date they intend to withdraw. However, Medtronic and the investigator will be bound by 
their obligation to complete the follow -up of subjects already participating in the study. The subjects 
must be followed according to the clinical protocol, and information obtained shall be reported to Medtronic on the appropriate CRF.  
Once the study is complete at the site, the investigator must submit a final report to their IRB and the 
sponsor per their IRB requirements. 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 50 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  15.10.  Study Contact Information  
Clinical Research  Medical Affairs 
Scott Chouinard  PhD 
Senior Director, Clinical Research 
Medtronic MITG  
Surgical Innovations  
15 Hampshire S treet  
Mansfield, MA 02048 
 
 Jennifer Mattingley MD  
Medical Affairs Director  
Lung Health, Surgical Innovations  
Minimally Invasive Therapies Group  
161 Cheshire Lane, Suite 100 Plymouth, MN 55441 
 
 
16. References  
 
1. National Cancer Institute, Cancer Therapy Evaluation Program, United States Department of Health and Human Services, National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Available at: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50. 
Accessed January 23, 2018.  
2. Bowling MR, Anciano CJ. Updates in Advanced Diagnostic Bronchoscopy: Electromagnetic 
Navigational Bronchoscopy Chasing the Solitary Pulmonary Nodule. Clin Pulm Med. 2017;24(2):60-5. doi: 10.1097/cpm.0000000000000191. PubMed PMID: 00045413-201703000-00002.  
3. Becker HD, Herth F, Ernst A, Schwarz Y. Bronchoscopic biopsy of peripheral lung lesions under electromagnetic guidance: A pilot study. J Bronchology Interv Pulmonol. 2005;12(1):9 -13. 
4. Gildea TR, Mazzone PJ, Karnak D, Meziane M, Mehta AC. Electromagnetic navigation diagnostic bronchoscopy: a prospective study. Am J Respir Crit Care Med. 2006;174(9):982- 9. doi: 
10.1164/rccm.200603-344OC. PubMe d PMID: 16873767; PubMed Central PMCID: PMC2648102.  
5. Schwarz Y, Greif J, Becker HD, Ernst A, Mehta A. Real -time electromagnetic navigation 
bronchoscopy to peripheral lung lesions using overlaid CT images: the first human study. Chest. 2006;129(4):988-94.  doi: 10.1378/chest.129.4.988. PubMed PMID: 16608948.  
6. Eberhardt R, Anantham D, Ernst A, Feller -Kopman D, Herth F. Multimodality bronchoscopic 
diagnosis of peripheral lung lesions: a randomized controlled trial. Am J Respir Crit Care Med. 
2007;176(1):36-41. doi: 10.1164/rccm.200612-1866OC. PubMed PMID: 17379850.  
7. Eberhardt R, Anantham D, Herth F, Feller-Kopman D, Ernst A. Electromagnetic navigation 
diagnostic bronchoscopy in peripheral lung lesions. Chest. 2007;131(6):1800 -5. doi: 
10.1378/chest.06-3016.  PubMed PMID: 17400670. 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 51 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  8. Makris D, Scherpereel A, Leroy S, Bouchindhomme B, Faivre JB, Remy J, et al. Electromagnetic 
navigation diagnostic bronchoscopy for small peripheral lung lesions. Eur Respir J. 
2007;29(6):1187-92. doi: 10.1183/09031936.00165306. PubMed PMID: 17360724.  
9. Wilson DS, Bartlett RJ. Improved diagnostic yield of bronchoscopy in a community practice: Combination of electromagnetic navigation system and rapid on -site evaluation. J Bronchology 
Interv Pulmonol. 2007;14(4):227-32 doi: 10.1097/LBR.0b013e31815a7b00.  
10. Bertoletti L, Robert A, Cottier M, Chambonniere ML, Vergnon JM. Accuracy and feasibility of electromagnetic navigated bronchoscopy under nitrous oxide sedation for pulmonary peripheral opacities: an outpatient study. Respiration . 2009;78(3):293-300. doi: 10.1159/000226128. 
PubMed PMID: 19546519. 
11. Lamprecht B, Porsch P, Pirich C, Studnicka M. Electromagnetic navigation bronchoscopy in 
combination with PET-CT and rapid on -site cytopathologic examination for diagnosis of 
peripher al lung lesions. Lung. 2009;187(1):55-9. doi: 10.1007/s00408-008-9120-8. PubMed 
PMID: 18836886. 
12. Eberhardt R, Morgan RK, Ernst A, Beyer T, Herth FJ. Comparison of suction catheter versus 
forceps biopsy for sampling of solitary pulmonary nodules guided b y electromagnetic 
navigational bronchoscopy. Respiration. 2010;79(1):54-60. doi: 10.1159/000232394. PubMed PMID: 19648733. 
13. Seijo LM, de Torres JP, Lozano MD, Bastarrika G, Alcaide AB, Lacunza MM, et al. Diagnostic yield of electromagnetic navigation bronchoscopy is highly dependent on the presence of a bronchus sign on CT imaging: results from a prospective study. Chest. 2010;138(6):1316-21. doi: 
10.1378/chest.09-2708. PubMed PMID: 20435658.  
14. Mahajan AK, Patel S, Hogarth DK, Wightman R. Electromagnetic navigational bronchoscopy: an 
effective and safe approach to diagnose peripheral lung lesions unreachable by conventional bronchoscopy in high -risk patients. J Bronchology Interv Pulmonol. 2011;18(2):133-7. doi: 
10.1097/LBR.0b013e318216cee6. PubMed PMID: 23169081. 
15. Brownback KR, Quijano F, Latham HE, Simpson SQ. Electromagnetic navigational bronchoscopy in the diagnosis of lung lesions. J Bronchology Interv Pulmonol. 2012;19(2):91 -7. doi: 
10.1097/LBR.0b013e31824dd9a1. PubMed PMID: 23207349.  
16. Jensen KW, Hsia DW, Seijo LM, Feller -Kopman DJ, Lamb C, Berkowitz D, et al. Multicenter 
experience with electromagnetic navigation bronchoscopy for the diagnosis of pulmonary nodules. J Bronchology Interv Pulmonol. 2012;19(3):195 -9. doi: 
10.1097/LBR.0b013e3182616ece. PubMed PMID: 23207460.  
17. Lamprecht B, Porsch P, Wegleitner B, Strasser G, Kaiser B, Studnicka M. Electromagnetic navigation bronchoscopy (ENB): Increasing diagnostic yield. Respir Med. 2012;106(5):710 -5. doi: 
10.1016/j.rmed.2012.02.002. PubMed PMID: 22391437. 
18. Pearlstein DP, Quinn CC, Burtis CC, Ahn KW, Katch AJ. Electromagnetic navigation bronchoscopy performed by thoracic surgeons: one center's early success. Ann Thorac Surg. 2012;93(3):944-9; discussion 9 -50. doi: 10.1016/j.athoracsur.2011.11.006. PubMed PMID: 22277964.  
19. Balbo PE, Bodini BD, Patrucco F, Della Corte F, Zanaboni S, Bagnati P, et al. Electromagnetic 
navigation bronchoscopy and rapid on site evaluation added to fluoroscopy -guided assisted 
bronchoscopy and rapid on site evaluation: improved yield in pulmonary nodules. Minerva Chir. 
2013;68(6):579-85. PubMed PMID: 24193290.  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 52 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  20. Karnak D, Ciledag A, Ceyhan K, Atasoy C, Akyar S, Kayacan O. Rapid on-site evaluation and low 
registration error enhance the success of electromagnetic navigation bronchoscopy. Ann Thorac 
Med. 2013;8(1):28-32. doi: 10.4103/1817-1737.105716. PubMed PMID: 23440066; PubMed Central PMCID: PMC3573554.  
21. Khan AY, Berkowitz D, Krimsky WS, Hogarth DK, Parks C, Bechara R. Safety of pacemakers and defibrillators in e lectromagnetic navigation bronchoscopy. Chest. 2013;143(1):75 -81. doi: 
10.1378/chest.12-0689. PubMed PMID: 22922452.  
22. Mohanasundaram U, Ho LA, Kuschner WG, Chitkara RK, Canfield J, Canfield LM, et al. The Diagnostic Yield of Navigational Bronchoscopy Performed with Propofol Deep Sedation. ISRN Endoscopy. 2013;2013:1-5. doi: 10.5402/2013/824693.  
23. Loo FL, Halligan AM, Port JL, Hoda RS. The emerging technique of electromagnetic navigation 
bronchoscopy -guided fine -needle aspiration of peripheral lung lesions: promising results in 50 
lesions. Cancer Cytopathol. 2014;122(3):191-9. doi: 10.1002/cncy.21373. PubMed PMID: 
24323803. 
24. Odronic SI, Gildea TR, Chute DJ. Electromagnetic navigation bronchoscopy -guided fine needle 
aspiration for the diagnosis of lung lesions. Diagn Cytopathol. 2014;42(12):1045-50. doi: 
10.1002/dc.23164. PubMed PMID: 24692403.  
25. Bowling MR, Kohan MW, Walker P, Efird J, Ben Or S. The effect of general anesthesia versus intravenous sedation on diagnostic yield and success in electromagnetic navigation bronchoscopy. J Bronchology Interv Pulmonol. 2015;22(1):5 -13. doi: 
10.1097/LBR.0000000000000120. PubMed PMID: 25590477.  
26. Al-Jaghbeer M, Marcus M, Durkin M, McGuire FR, Iftikhar IH. Diagnostic yield of electromagnetic navigational bronch oscopy. Ther Adv Respir Dis. 2016;10(4):295-9. doi: 
10.1177/1753465816637053. PubMed PMID: 26944363.  
27. Garwood SK, ClenDening P, Hevelone ND, Hood KL, Pidgeon S, Wudel LJ. Navigational 
bronchoscopy at a community hospital: clinical and economic outcomes. Lung Cancer 
Management. 2016;5(3):131-40. doi: 10.2217/lmt-2016-0015.  
28. Ost DE, Ernst A, Lei X, Kovitz KL, Benzaquen S, Diaz -Mendoza J, et al. Diagnostic yield and 
complications of bronchoscopy for peripheral lung lesions. Results of the AQuIRE Registry . Am J 
Respir Crit Care Med. 2016;193(1):68-77. doi: 10.1164/rccm.201507-1332OC. PubMed PMID: 26367186. 
29. Ozgul G, Cetinkaya E, Ozgul MA, Abul Y, Gencoglu A, Kamiloglu E, et al. Efficacy and safety of 
electromagnetic navigation bronchoscopy with or without radial endobronchial ultrasound for peripheral lung lesions. Endosc Ultrasound. 2016;5(3):189 -95. doi: 10.4103/2303-9027.183979. 
PubMed PMID: 27386477. 
30. Bowling MR, Brown C, Anciano CJ. Feasibility and Safety of the Transbronchial Access Tool for Peripheral Pulmonary Nodule and Mass. Ann Thorac Surg. 2017;104:443-9. doi: 
10.1016/j.athoracsur.2017.02.035. PubMed PMID: 28527967.  
31. Copeland S, Kambali S, Berdine G, Alalawi R. Electromagnetic navigational bronchoscopy in patients with solitary pulmonary nodules. The Southwest Respiratory and Critical Care 
Chronicles. 2017;5(17):12- 6. Epub 2017-01-15. doi: 10.12746/swrccc2017.0517.235.  
32. Mukherjee S, Chacey M. Diagnostic Yield of Electromagnetic Navigation Bronchoscopy Using a 
Curved -tip Catheter to Aid in the Diagnosis of Pulmonary Lesions. J Bronchology Interv 
Pulmonol. 2017;24(1):35-9. doi: 10.1097/LBR.0000000000000326. PubMed PMID: 27623421.  

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 53 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  33. Saenghirunvattana S, Bechara R, Saenghirunvattana C, Gonzales MC, Sutthisri K, Siangpro C. 
Electromagnetic Navigation Bronchoscopy. BKK Med J. 2017;13(1):37 -40. 
34. Sun J, Xie F, Zheng X, Jiang Y, Zhu L, Mao X, et al. Learning curve of electromagnetic navigation 
bronchoscopy for diagnosing peripheral pulmonary nodules in a single institution. Translational Cancer Research. 2017.  
35. Gex G, Pralong JA, Combescure C, Seijo L, Rochat T, Soccal PM. Diagnostic yield and safety of 
electromagnetic navigation bronchoscopy for lung nodules: a systematic review and meta -
analysis. Respiration. 2014;87(2):165-76. doi: 10.1 159/000355710. PubMed PMID: 24401166.  
36. DiBardino DM, Yarmus LB, Semaan RW. Transthoracic needle biopsy of the lung. J Thorac Dis. 
2015;7(Suppl 4):S304-16. doi: 10.3978/j.issn.2072-1439.2015.12.16. PubMed PMID: 26807279; PubMed Central PMCID: PMC4700361.  
37. Khandhar SJ, Bowling MR, Fla ndes J, Gildea TR, Hood KL, Krimsky WS, et al. Electromagnetic 
navigation bronchoscopy to access lung lesions in 1,000 subjects: first results of the prospective, multicenter NAVIGATE study. BMC Pulm Med. 2017;17(1):59. doi: 10.1186/s12890-017-0403-9.  
38. Herth FJ, Eberhardt R, Becker HD, Ernst A. Endobronchial ultrasound -guided transbronchial lung 
biopsy in fluoroscopically invisible solitary pulmonary nodules: a prospective trial. Chest. 
2006;129(1):147-50. doi: 10.1378/chest.129.1.147. PubMed PMID: 16424425.  
39. Folch EE, Bowling MR, Gildea TR, Hood KL, Murgu SD, Toloza EM, et al. Design of a prospective, 
multicenter, global, cohort study of electromagnetic navigation bronchoscopy. BMC Pulm Med. 2016;16(1):60. doi: 10.1186/s12890-016 -0228-y. PubMed PMID: 27113209. 
40. Steinfort DP, Einsiedel P, Irving LB. Radiation dose to patients and clinicians during 
fluoroscopically-guided biopsy of peripheral pulmonary lesions. Respir Care. 2010;55(11):1469-
74. Epub 2010/10/29. PubMed PMID: 20979674.  
41. Hohenforst-Sc hmidt W, Banckwitz R, Zarogoulidis P, Vogl T, Darwiche K, Goldberg E, et al. 
Radiation exposure of patients by cone beam CT during endobronchial navigation -a phantom 
study. J Cancer. 2014;5(3):192.  
 
  
  
 
  
 
 

Fluoroscopic Navigation Clinical Investigation Plan  
  
MDT18004ILSFNV Version  1.0 Page 54 of 54 
 
This document is electronically controlled    056-F275, v3.0 Clinical Investigation Plan Template 
  
  18. Version History  
Version  Summary of Changes  Author(s)/Title 
1.0 • Not applicable (new document ) Sean Pidgeon , Senior Clinical Research 
Specialist 
Kristin Hood, Senior Principal Medical 
Writer 
 
